» Authors » Kristina Lovgren

Kristina Lovgren

Explore the profile of Kristina Lovgren including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 2958
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Forsare C, Vistrand S, Ehinger A, Lovgren K, Ryden L, Ferno M, et al.
Cancers (Basel) . 2022 Feb; 14(4). PMID: 35205688
Previous studies have shown that high intratumoral stromal content is associated with a worse prognosis in breast cancer, especially in the triple-negative subtype. However, contradictory results have been reported for...
2.
Sjodahl G, Abrahamsson J, Holmsten K, Bernardo C, Chebil G, Eriksson P, et al.
Eur Urol . 2021 Nov; 81(5):523-532. PMID: 34782206
Background: For muscle-invasive bladder cancer (MIBC), no tissue biomarkers are available for clinical use to predict response to neoadjuvant chemotherapy. Objective: To investigate how molecular subtypes impact pathological response and...
3.
Ciesla M, Ngoc P, Cordero E, Martinez A, Morsing M, Muthukumar S, et al.
Mol Cell . 2021 Mar; 81(7):1453-1468.e12. PMID: 33662273
Splicing is a central RNA-based process commonly altered in human cancers; however, how spliceosomal components are co-opted during tumorigenesis remains poorly defined. Here we unravel the core splice factor SF3A3...
4.
Jorgensen C, Forsare C, Bendahl P, Falck A, Ferno M, Lovgren K, et al.
Breast Cancer Res Treat . 2020 Apr; 181(2):369-381. PMID: 32300922
Purpose: The study aimed to investigate expression of epithelial-to-mesenchymal transition (EMT)-related proteins and phenotypes during breast cancer progression and to relate this to patient outcome. Methods: Protein expression patterns of...
5.
Cabrita R, Mitra S, Sanna A, Ekedahl H, Lovgren K, Olsson H, et al.
Cancers (Basel) . 2020 Apr; 12(3). PMID: 32245160
Checkpoint blockade therapies have changed the clinical management of metastatic melanoma patients considerably, showing survival benefits. Despite the clinical success, not all patients respond to treatment or they develop resistance....
6.
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al.
Nature . 2020 Apr; 580(7801):E1. PMID: 32238929
An Amendment to this paper has been published and can be accessed via a link at the top of the paper.
7.
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al.
Nature . 2020 Jan; 577(7791):561-565. PMID: 31942071
Checkpoint blockade therapies that reactivate tumour-associated T cells can induce durable tumour control and result in the long-term survival of patients with advanced cancers. Current predictive biomarkers for therapy response...
8.
Sjodahl G, Eriksson P, Patschan O, Marzouka N, Jakobsson L, Bernardo C, et al.
Int J Cancer . 2019 Oct; 146(9):2636-2647. PMID: 31609466
Molecular changes occurring during invasion and clinical progression of cancer are difficult to study longitudinally in patient-derived material. A unique feature of urothelial bladder cancer (UBC) is that patients frequently...
9.
Narbe U, Sjostrom M, Forsare C, Bendahl P, Alkner S, Leeb-Lundberg L, et al.
Breast Cancer Res Treat . 2019 Feb; 175(2):305-316. PMID: 30796653
Purpose: According to the 2017 St Gallen surrogate definitions of the intrinsic subtypes, Ki67, progesterone receptor (PR) and Nottingham histological grade (NHG) are used for prognostic classification of estrogen receptor...
10.
Sjodahl G, Eriksson P, Lovgren K, Marzouka N, Bernardo C, Nordentoft I, et al.
Mod Pathol . 2018 Jul; 31(12):1869-1881. PMID: 29967424
Molecular subtypes of muscle-invasive bladder tumors have emerged as a promising research tool with potential to stratify patients for neoadjuvant treatment. Prior to radical cystectomy, the utility of molecular classification...